New insider activity at Insulet ( (PODD) ) has taken place on December 8, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Director Timothy C. Stonesifer has made a notable investment in Insulet by purchasing 962 shares of the company’s stock, amounting to a total value of $299,884.
Recent Updates on PODD stock
In the past 24 hours, Insulet has seen a series of positive developments that have influenced its stock price targets. The company announced FDA 510(k) clearance for enhancements to its Omnipod 5 Automated Insulin Delivery System, which is expected to strengthen its position in the diabetes technology market. Analysts from Canaccord, Truist, RBC Capital, and BTIG have raised their price targets for Insulet, citing the company’s promising growth potential and strategic initiatives outlined during its Investor Day presentation. These updates include a robust financial outlook for 2025-2028, significant growth prospects in an under-penetrated diabetes market, and ambitious long-term growth targets. The analysts believe that Insulet’s leadership in the patch category and its innovative strategies will drive sustained growth, justifying the increased price targets.
Spark’s Take on PODD Stock
According to Spark, TipRanks’ AI Analyst, PODD is a Outperform.
Insulet’s strong financial performance and positive earnings call are major strengths, reflecting robust growth and operational efficiency. However, the high valuation and bearish technical indicators suggest caution. Recent corporate events are positive but have a moderate impact on the overall score.
To see Spark’s full report on PODD stock, click here.
More about Insulet
YTD Price Performance: 18.55%
Average Trading Volume: 653,335
Technical Sentiment Signal: Buy
Current Market Cap: $21.42B